ANIX

2.93

3.93% -0.12

Dopo l'orario di chiusura: 3.33 0.40 +13.65%

Anixa Biosciences Inc (ANIX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.05

Aprire:

$3.03

Volume 24 ore:

188.08K

Relative Volume:

1.11

Capitalizzazione di mercato:

$99.69M

Reddito:

$210.00K

Utile/perdita netta:

$-10.40M

Rapporto P/E:

-9.3045

EPS:

-0.3149

Flusso di cassa netto:

$-6.88M

1 W Prestazione:

+4.64%

1M Prestazione:

+18.15%

6M Prestazione:

-10.67%

1 anno Prestazione:

-8.72%

Intervallo 1D:

$2.87

$3.08

Intervallo di 1 settimana:

$2.74

$3.4842

Portata 52W:

$2.32

$5.4566

Anixa Biosciences Inc Stock (ANIX) Company Profile

Nome

Anixa Biosciences Inc

Settore

Healthcare (1094)

Industria

Biotechnology (615)

Telefono

408-708-9808

Indirizzo

3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE

Dipendente

Cinguettio

@anixabio

Prossima data di guadagno

2026-06-10

Ultimi documenti SEC

ANIX's Discussions on Twitter

Compare ANIX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ANIX Anixa Biosciences Inc	2.93	103.77M	210.00K	-10.40M	-6.88M	-0.3149
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.93	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.50	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-03-21	Iniziato	Maxim Group	Buy
2022-12-23	Iniziato	Chardan Capital Markets	Buy
2021-04-12	Iniziato	H.C. Wainwright	Buy

Anixa Biosciences Inc Borsa (ANIX) Ultime notizie

08:30 AM

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Trial to Highest Dose Cohort - HLTH

08:30 AM

01:47 AM

Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial - Moomoo

01:47 AM

Jul 06, 2026

Anixa doses first patient in highest cohort of ovarian trial - Investing.com

Jul 06, 2026

Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level. - Bitget

Jul 06, 2026

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date - PR Newswire

Jul 06, 2026

Jul 04, 2026

Anixa Biosciences secures Korean patent for breast cancer vaccine - Yahoo Finance

Jun 30, 2026

Anixa Biosciences Granted First Korean Patent for its Breast Can - GuruFocus

Jun 30, 2026

Jun 29, 2026

Anixa receives South Korean patent for breast cancer vaccine - Investing.com

Jun 29, 2026

Anixa Biosciences (ANIX) Secures Patent for Breast Cancer Vaccine Technology - GuruFocus

Jun 29, 2026

Anixa receives South Korean patent for breast cancer vaccine By Investing.com - Investing.com South Africa

Jun 29, 2026

Anixa Secures Patent for Breast Cancer Vaccine in South Korea - Intellectia AI

Jun 29, 2026

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 - PR Newswire

Jun 29, 2026

Jun 27, 2026

Anixa Biosciences, Inc. Actuals & Estimates (NASDAQ:ANIX) - TradingView

Jun 27, 2026

Jun 26, 2026

Anixa Biosciences, Inc. Actuals & Estimates (DUS:CY71) - TradingView

Jun 26, 2026

Price to sales forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView

Jun 26, 2026

Anixa presents breast cancer vaccine, ovarian CAR-T trial data - Investing.com UK

Jun 26, 2026

Anixa Biosciences (ANIX) Showcases Immunotherapy Progress at Key Symposium - GuruFocus

Jun 26, 2026

Anixa presents breast cancer vaccine, ovarian CAR-T trial data By Investing.com - Investing.com Australia

Jun 26, 2026

Enterprise value to revenue forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView

Jun 26, 2026

Anixa Biosciences stock falls despite Phase 1 trial updates By Investing.com - Investing.com Nigeria

Jun 26, 2026

Anixa Biosciences stock falls despite Phase 1 trial updates - Investing.com

Jun 26, 2026

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium - Barchart.com

Jun 26, 2026

Enterprise value to EBIT forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView

Jun 26, 2026

Price to earnings forward of Anixa Biosciences, Inc. – NASDAQ:ANIX - TradingView

Jun 26, 2026

ANIX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 25, 2026

Anixa Biosciences, Inc. Actuals & Estimates (SWB:CY71) - TradingView

Jun 25, 2026

Here's Why You Should Add ANIX Stock to Your Portfolio Now - The Globe and Mail

Jun 25, 2026